OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Charlotte Primard; Elodie Monchâtre-Leroy; Judith Del Campo; Séverine Valsesia; Elsa Nikly; Marion Chevandier; Franck Boué; Alexandre Servat; Marine Wasniewski; Evelyne Picard-Meyer; Thomas Courant; Nicolas Collin; Francisco J. Salguero; Alexandre Le Vert; Delphine Guyon-Gellin; Florence Nicolas

doi:10.3389/fimmu.2023.1188605

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Charlotte Primard, Elodie Monchâtre-Leroy, Judith Del Campo, Séverine Valsesia, Elsa Nikly, Marion Chevandier, Franck Boué, Alexandre Servat, Marine Wasniewski, Evelyne Picard-Meyer, Thomas Courant, Nicolas Collin, Francisco J. Salguero, Alexandre Le Vert, Delphine Guyon-Gellin^*, Florence Nicolas

^*Corresponding author for this work

Research & Technical Staff

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM^®, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.

Original language	English
Article number	1188605
Journal	Frontiers in Immunology
Volume	14
DOIs	https://doi.org/10.3389/fimmu.2023.1188605
Publication status	Published - 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Primard, Monchâtre-Leroy, Del Campo, Valsesia, Nikly, Chevandier, Boué, Servat, Wasniewski, Picard-Meyer, Courant, Collin, Salguero, Le Vert, Guyon-Gellin and Nicolas.

Keywords

T cell immunity
broad-spectrum protection
cross-reactive immune responses
lung histopathology
lung viral load
recombinant nucleocapsid
sarbecovirus vaccine
universal vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fimmu.2023.1188605

Cite this

Primard, C., Monchâtre-Leroy, E., Del Campo, J., Valsesia, S., Nikly, E., Chevandier, M., Boué, F., Servat, A., Wasniewski, M., Picard-Meyer, E., Courant, T., Collin, N., Salguero, F. J., Le Vert, A., Guyon-Gellin, D., & Nicolas, F. (2023). OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Frontiers in Immunology, 14, Article 1188605. https://doi.org/10.3389/fimmu.2023.1188605

@article{9d6a9d087f284d15a235d56c1deef0e8,

title = "OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model",

abstract = "Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM{\textregistered}, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.",

keywords = "T cell immunity, broad-spectrum protection, cross-reactive immune responses, lung histopathology, lung viral load, recombinant nucleocapsid, sarbecovirus vaccine, universal vaccine",

author = "Charlotte Primard and Elodie Monch{\^a}tre-Leroy and {Del Campo}, Judith and S{\'e}verine Valsesia and Elsa Nikly and Marion Chevandier and Franck Bou{\'e} and Alexandre Servat and Marine Wasniewski and Evelyne Picard-Meyer and Thomas Courant and Nicolas Collin and Salguero, {Francisco J.} and {Le Vert}, Alexandre and Delphine Guyon-Gellin and Florence Nicolas",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Primard, Monch{\^a}tre-Leroy, Del Campo, Valsesia, Nikly, Chevandier, Bou{\'e}, Servat, Wasniewski, Picard-Meyer, Courant, Collin, Salguero, Le Vert, Guyon-Gellin and Nicolas.",

year = "2023",

doi = "10.3389/fimmu.2023.1188605",

language = "English",

volume = "14",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Primard, C, Monchâtre-Leroy, E, Del Campo, J, Valsesia, S, Nikly, E, Chevandier, M, Boué, F, Servat, A, Wasniewski, M, Picard-Meyer, E, Courant, T, Collin, N, Salguero, FJ, Le Vert, A, Guyon-Gellin, D & Nicolas, F 2023, 'OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model', Frontiers in Immunology, vol. 14, 1188605. https://doi.org/10.3389/fimmu.2023.1188605

TY - JOUR

T1 - OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

AU - Primard, Charlotte

AU - Monchâtre-Leroy, Elodie

AU - Del Campo, Judith

AU - Valsesia, Séverine

AU - Nikly, Elsa

AU - Chevandier, Marion

AU - Boué, Franck

AU - Servat, Alexandre

AU - Wasniewski, Marine

AU - Picard-Meyer, Evelyne

AU - Courant, Thomas

AU - Collin, Nicolas

AU - Salguero, Francisco J.

AU - Le Vert, Alexandre

AU - Guyon-Gellin, Delphine

AU - Nicolas, Florence

N1 - Publisher Copyright: Copyright © 2023 Primard, Monchâtre-Leroy, Del Campo, Valsesia, Nikly, Chevandier, Boué, Servat, Wasniewski, Picard-Meyer, Courant, Collin, Salguero, Le Vert, Guyon-Gellin and Nicolas.

PY - 2023

Y1 - 2023

N2 - Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM®, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.

AB - Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM®, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.

KW - T cell immunity

KW - broad-spectrum protection

KW - cross-reactive immune responses

KW - lung histopathology

KW - lung viral load

KW - recombinant nucleocapsid

KW - sarbecovirus vaccine

KW - universal vaccine

UR - http://www.scopus.com/inward/record.url?scp=85164015733&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2023.1188605

DO - 10.3389/fimmu.2023.1188605

M3 - Article

C2 - 37409116

AN - SCOPUS:85164015733

SN - 1664-3224

VL - 14

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1188605

ER -

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this